© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription. Molybdenum Cofactor Deficiency (MoCD) is a rare ...
BASF and Glycosyn will partner to develop human milk oligosaccharides for use in dietary supplements, functional nutrition, and medical food. Manufacturing of HMOs such as 2′-fucosyllactose was ...
Nov. 5 (BusinessDesk) - GlycoSyn is seeking new global customers for kifunensine, a key ingredient in the manufacture of a drug for the treatment of rare genetic disorders that's worth 20 times more ...
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription. GlycoSyn is seeking new global customers for ...
FrieslandCampina Domo has entered into a joint venture with Glycosyn. AMERSFOORT, THE NETHERLANDS – Ingredient company FrieslandCampina Domo has entered into a joint venture with Glycosyn, Waltham, ...
BOSTON, Nov. 8, 2018 /PRNewswire/ -- Today, Ginkgo Bioworks, the organism company, and Glycosyn LLC, a biotech company developing components of human milk, announced a $14MM deal to optimize and scale ...
The organism engineering company Ginkgo Bioworks and the biotech firm Glycosyn are joining to develop human milk oligosaccharides as ingredients for products that foster a healthy gut microbiome. The ...
New Zealand company GlycoSyn is seeking new global customers for kifunensine, a key ingredient in the manufacture of a drug for the treatment of rare genetic disorders that is worth 20 times more than ...
MELBOURNE, Australia, & LOWER HUTT, New Zealand--(BUSINESS WIRE)--Mimotopes Pty Ltd, a subsidiary of Commonwealth Biotechnologies Inc, Richmond, VA (Nasdaq Capital Market: CBTE), and GlycoSyn, a ...
FrieslandCampina has announced a partnership with US-based pharmaceutical group Glycosyn to produce ingredients for the infant nutrition market. The two have signed a technology and partnership ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results